BioTuesdays: Synthetic Biologics’ sniper approach to infectious diseases
Taking a page out of the oncology sector and its approach to targeting specific cancers with new biologics, Synthetic Biologics (NYSE MKT:SYN) is developing treatments for infectious diseases in much the same way, with a number of milestones on the horizon for 2014.
“This approach, using biologics and monoclonal antibodies, has not been taken in the infectious disease space,” CEO Jeffrey Riley says in an interview with BioTuesdays. “We are taking a sniper-like approach to go after each bug.”
Mr. Riley is part of a new management team that restructured Synthetic in mid-2012. “When we came into the company and began looking for commercial programs, infectious diseases kept coming up, because they are a large unmet medical need,” he recalls. “The interesting thing about infectious diseases is that if we can kill them in an animal model, we generally can kill them in a human model.”